Array biopharma inc (ARRY)
CashFlow / Quarterly
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

-37,494

-11,362

-24,811

-52,448

-22,851

-34,053

-37,994

-29,592

-35,317

-23,301

-28,608

-25,014

-22,675

-24,164

-20,987

-12,734

58,307

-8,611

-27,593

-28,237

-24,932

-16,408

-15,680

-17,651

-21,593

-10,930

-11,768

-8,027

-8,168

-3,806

-3,580

-21,752

-11,500

-12,442

-10,630

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

537

536

533

536

562

561

577

569

528

496

475

251

419

386

473

926

971

929

876

930

1,223

1,250

1,103

1,000

1,072

1,132

1,146

1,211

1,235

1,296

1,334

3,250

1,422

1,454

1,490

Non-cash interest expense

1,591

1,561

1,441

1,321

1,291

1,679

1,961

1,912

1,872

1,741

1,698

1,656

1,613

1,563

1,543

1,504

1,468

1,431

1,396

1,359

1,324

1,306

1,269

1,210

1,108

1,129

1,029

-

-

-

1,145

1,258

1,804

1,798

1,517

Share-based compensation expense

8,321

5,530

4,812

5,569

4,719

3,236

5,583

3,067

2,890

2,095

1,913

1,866

1,805

1,853

1,759

2,683

1,914

2,043

1,169

1,251

1,072

1,039

969

1,064

823

767

795

719

476

589

567

558

769

903

1,098

Realized gain or loss on investments, net

1

0

35

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,093

865

-67

Impairment loss related to cost method investment

-

-

-

-

-

-

-

0

0

0

1,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing fees on notes payable

-

-

-

-

-

-

-

0

0

123

117

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of notes payable

0

130

-65

3,099

-300

300

200

4,700

-1,300

-600

-200

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash license revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,500

0

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

9,415

-22,133

12,294

-12,074

14,188

3,369

-4,678

-1,228

-10,615

9,184

-5,364

-11,619

18,059

19,358

7,197

4,191

3,952

-1,122

571

996

-1,277

4,696

-8,581

6,031

1,872

-199

816

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

7,609

24,072

9,844

1,969

425

1,559

-886

-3,139

953

-1,471

-2,522

4,011

-484

399

426

2,069

83

-1,780

888

1,512

654

118

-323

-323

594

1,670

-1,195

360

452

-251

-1,605

-10,497

10,642

-1,089

1,576

Accounts payable and other accrued expenses

1,385

-6,100

4,268

1,425

1,752

1,252

1,287

80

2,510

-242

-3,352

-6,709

3,548

4,349

2,743

-2,366

-2,323

3,630

-54

-793

3,599

22

-962

-2,409

2,320

358

-1,593

951

-355

-21

509

-468

1,412

-907

-1,210

Accrued outsourcing costs

-2,176

7,271

2,411

-2,481

7,033

-10,232

6,145

780

1,555

3,499

6,414

-4,082

2,741

2,822

257

2,466

748

479

3,669

2,004

680

1,006

774

516

551

61

-946

-404

1,427

-216

-661

617

303

348

-927

Accrued compensation and benefits

2,339

-3,089

1,632

5,217

3,573

-5,413

2,013

2,735

2,048

-4,765

1,521

1,920

1,078

-3,129

1,257

830

1,767

-4,509

1,210

988

1,807

-4,614

547

1,808

2,575

-4,074

1,642

1,869

902

-2,749

1,077

-343

-2,839

-1,745

1,345

Co-development liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,305

5,370

3,494

4,188

5,277

-5,514

1,214

3,996

3,024

-6,128

920

-

-

-

-

-

-

-

-

Deferred rent

23

-161

-167

-167

35

187

-88

-157

1,228

209

284

535

531

-446

-445

-441

-916

-932

-947

-914

-913

-911

-907

-873

-875

-872

-869

-834

-835

-2,492

829

-5,562

796

795

791

Deferred revenue

-1,053

-1,068

-2,760

-544

-2,876

-11,315

-2,926

32,942

-2,115

-487

-4,676

14,467

27,517

-5,887

1,734

-2,330

5,411

-858

-639

-516

-4,775

-5,637

6,121

-8,237

-8,513

-12,326

-12,138

-10,284

-13,383

-20,314

12,368

-11,930

-4,417

-2,104

-12,020

Other non-current liabilities

-436

183

-51

-261

297

137

34

104

-83

140

23

40

-169

153

85

-49

-350

112

109

10

-114

72

36

4

-247

104

33

-

-

-

-

-2,129

391

1,212

723

Other liabilities and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-890

-115

-8

-

-

-

-

Net cash used in operating activities

-43,988

-8,638

-34,800

-28,629

-20,978

-52,132

-18,044

17,307

-14,451

-27,605

-14,605

-7,462

-1,167

-42,257

-19,204

-27,265

38,255

1,986

-18,769

-22,238

-15,129

-33,203

-1,112

-14,083

-22,221

-29,393

-21,370

-9,978

-17,417

-19,678

13,527

-11,790

-21,204

-12,054

-20,914

Cash flows from investing activities
Purchases of property and equipment

612

578

265

110

910

188

24

213

1,574

687

1,046

433

1,223

1,092

411

433

354

1,237

483

1,249

640

527

198

329

547

660

804

339

172

493

433

582

196

755

368

Proceeds from investment

0

0

35

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from investment

-

-

87,308

-

-

-

104,468

36,116

153,922

151,334

46,182

37,182

27,115

33,522

41,331

108,488

30,726

35,422

28,272

15,145

12,263

38,786

29,408

37,276

11,425

49,606

12,416

10,157

36,242

139

4,801

72

23,932

17,896

11,527

Purchases of marketable securities

105,017

100,682

101,279

114,556

46,820

46,675

44,746

50,678

182,257

50,799

48,695

39,191

34,568

73,628

60,949

34,562

58,628

24,709

25,717

30,436

27,151

24,351

18,760

32,347

18,704

18,166

27,484

13,124

379

4,615

15,937

21,946

38,965

36,801

31,711

Net cash used in investing activities

-51,642

-46,687

13,741

67,213

-11,399

-187,105

-59,746

14,349

27,290

-101,222

1,467

1,576

6,230

39,014

19,207

-70,609

27,548

-11,950

-3,038

14,042

14,248

-14,962

-10,846

-5,258

6,732

-32,100

14,264

2,628

-36,035

3,983

10,703

21,292

14,837

18,150

19,816

Proceeds from exercise of stock options and shares issued under the employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,398

93

Net proceeds from the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

24,845

5,345

29,399

15,411

0

0

75,555

0

-

-

-

-

1,450

1,604

1,487

1,519

Payments of Stock Issuance Costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

108

614

5

512

127

443

470

2

13

4,644

0

-

-

-

-

-

-

-

-

Net proceeds from notes payable at fair value

-

-

-

-

-

-

-

-

0

-123

9,883

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of financing fees on notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from employee stock purchases and options exercised

11,413

64

1,123

2,501

3,671

13,180

1,423

46

789

1,251

258

-28

142

1,254

664

881

2,275

1,192

50

276

647

1,349

1,421

581

85

1,093

361

273

17

826

53

-

-

-

-

Payment of note payable

0

0

15,000

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,702

280

15

-

74

82

68

Proceeds from the modification of long-term debt, net

0

0

33,776

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment for debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-9

95

4,188

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

45,172

71,912

36,818

2,309

41,181

8,874

247,271

10,528

8,125

125,770

22,382

26

142

4,138

664

12,095

7,522

31,280

45

24,609

5,865

30,314

16,267

36,079

-78

72,004

361

124

56,114

3,691

38

1,243

1,530

2,803

1,544

Net increase in cash and cash equivalents

-

16,587

15,759

-

-

-230,363

169,481

42,184

20,964

-3,057

9,244

-5,860

5,205

895

667

-85,779

73,325

21,316

-21,762

16,413

4,984

-17,851

4,309

16,738

-15,567

10,511

-6,745

-7,226

2,662

-12,004

24,268

10,745

-4,837

8,899

446

Supplemental disclosure of cash flow information
Cash paid for interest

437

2,062

1,151

1,766

99

2,072

89

2,062

81

2,113

130

2,114

128

2,103

121

2,108

119

2,102

121

2,103

119

2,003

124

1,375

1,726

1,728

1,735

1,731

1,731

1,735

1,811

2,011

2,372

2,373

2,349

Change in unrealized gain (loss) on marketable securities

274

203

149

296

-81

-634

34

10

-36

-61

4

-7

51

-54

12

-9,793

-3,665

-1,059

14,520

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-